GlassScriptPhysician profile
George A Apergis
NPI 1760657183
$4,483.76
in general payments reported to CMS, 2019-2025
31 companies · $498 in 2025
The $498 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $528 · 2021: $745 · 2022: $639 · 2023: $895 · 2024: $475 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.99 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $925.91 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Insmed, INC. | $711.54 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $574.64 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Otsuka America Pharmaceutical, INC. | $315.59 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.79 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $191.86 | 2019 | |
| Amgen INC. | $172.80 | 2023-2025 | Tezspire |
| Genzyme Corporation | $166.60 | 2025 | |
| Amarin Pharma, INC. | $143.58 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $139.30 | 2023 | Opsumit, Uptravi |
| Inogen, INC. | $123.78 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Teva Pharmaceuticals USA, INC. | $105.65 | 2021-2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $75.48 | 2021-2024 | Xarelto |
| Verona Pharma, INC. | $66.28 | 2025 | Ohtuvayre |
| Philips North America LLC | $62.98 | 2019-2024 | (Ak6) Vest Therapy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $54.23 | 2021 | |
| Pfizer INC. | $52.90 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $45.01 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.72 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $41.31 | 2021-2023 | |
| Circassia INC. | $37.16 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $31.65 | 2020 | |
| Viatris Specialty LLC | $31.15 | 2025 | Yupelri |
| Abbvie INC. | $25.00 | 2020 | |
| Avanir Pharmaceuticals, INC. | $22.82 | 2022 | |
| Gilead Sciences, INC. | $22.62 | 2022 | |
| Neurocrine Biosciences, INC. | $21.00 | 2020 | |
| Urovant Sciences INC | $19.86 | 2022 | |
| Lundbeck LLC | $19.85 | 2023 | Rexulti |
| Genentech USA, INC. | $19.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Apergis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.